This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
AM levels increase during inflammation but are less significant in CVDs; AM's half-life is under 30 minutes.
Why it matters
Understanding the role of AM in cardiovascular health could lead to better treatment options. The development of longer-lasting AM derivatives may enhance therapeutic applications.
How the study worked
The study is a review of existing research on adrenomedullin and its derivatives in relation to cardiovascular diseases.
What this study cannot tell us
The short half-life of AM limits its therapeutic use, and early human studies have not been successful for CVD applications.
Read the original research
Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.
Hypertension research : official journal of the Japanese Society of Hypertension, 45(3), 389-400
Citation
Kita, Toshihiro; Kitamura, Kazuo. (2022). Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases.. Hypertension research : official journal of the Japanese Society of Hypertension, 45(3), 389-400. https://doi.org/10.1038/s41440-021-00806-y